智通财经APP获悉，艾伯维(ABBV.US)已同意以最多21亿美元现金收购临床阶段生物技术公司Capstan Therapeutics。该交易尚需满足惯常成交条件。 据悉，Capstan的首要研发重点是开发体内CAR-T疗法，旨在结合CAR-T疗法的强大疗效与“现成可用”产品的便利性，用于治疗自身 ...

Capstan的领先资产CPTX2309是一种靶向脂质纳米颗粒（tLNP），可将编码抗CD19嵌合抗原受体（CAR）的mRNA递送至体内表达CD8的细胞毒性T细胞，是治疗B细胞介导自身免疫性疾病的潜在同类首创产品。 B细胞在自身免疫性疾病的发病机制中起重要作用，CD19是表达在B细胞 ...

艾伯维(ABBV.US)已同意以最多21亿美元现金收购临床阶段生物技术公司Capstan Therapeutics。该交易尚需满足惯常成交条件。 据悉，Capstan的首要研发重点是开发体内CAR-T疗法，旨在结合CAR-T疗法的强大疗效与“现成可用”产品的便利性，用于治疗自身免疫性疾病。

2025年9月13日，在CSGCT大会“下一代免疫细胞疗法浪潮 - In Vivo CAR-T”分论坛上，一场关于细胞治疗未来的深度对话引发行业震动。昆翎医药联合创始人兼首席战略官、谱新生物联合创始人兼联席董事长张丹、华中科技大学同济医学院附属协和医院血液科主任医师梅 ...

June 30 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product ...

前述内容由第一财经“星翼大模型”智能生成，相关AI内容力求但不保证准确性、时效性、完整性等。请用户注意甄别，第一财经不承担由此产生的任何责任。 如您有疑问或需要更多信息，可以联系我们 [email protected] 该方法类似于mRNA疫苗，仅需简单注射，就能在 ...

AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a “high-risk, high-reward” clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T ...

The landmark minimally invasive procedures were performed at Hospital Clínico Universidad Católica in Santiago Chile, by Dr. Gonzalo Martinez, MD MPhil, Director Endovascular Therapy Center at ...

(Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental ...

With $31.4 million in new funding, the company will bring the benefits of robotics to one of the few remaining untouched areas of medicine, structural heart SANTA CRUZ, Calif.--(BUSINESS ...

SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with ...